Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – December 8, 2021 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call - Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_6JzMh8UaS_CJkFpBJSlgHg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 931 5637 1121
Passcode: 12421766

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. November 10, 2021 DUR Board Meeting Minutes
   B. November 10, 2021 DUR Board Recommendations Memorandum

Items to be presented by Dr. Ha, Dr. Travers, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Academic Detailing (AD) Program Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for November 2021
   B. Medication Coverage Activity for November 2021
   C. AD Program Update

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

5. **Action Item – Maintenance Drug List – See Appendix C**
   A. Introduction
   B. SoonerCare Maintenance Drug List
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Opzelura™ (Ruxolitinib 1.5% Cream) – See Appendix D**
   A. Market News and Updates
   B. Opzelura™ (Ruxolitinib 1.5% Cream) Product Summary

C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Abecma® (Idecabtagene Vicleucel), Farydak® (Panobinostat), and Pepaxto® (Melphalan Flufenamide) and Update the Approval Criteria for the Multiple Myeloma Medications – See Appendix E**
   A. Market News and Updates
   B. Abecma® (Idecabtagene Vicleucel) Product Summary
   C. Farydak® (Panobinostat) Product Summary
   D. Pepaxto® (Melphalan Flufenamide) Product Summary
   E. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Jemperli® (Dostarlimab-gxly) and Update the Renal Cell Carcinoma (RCC) Approval Criteria for Keytruda® (Pembrolizumab) and Lenvima® (Lenvatinib) – See Appendix F**
   A. Market News and Updates
   B. Jemperli® (Dostarlimab-gxly) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. **Action Item – Annual Review of Skin Cancer Medications – See Appendix G**
   A. Introduction
   B. Current Prior Authorization Criteria
   C. Utilization of Skin Cancer Medications
   D. Prior Authorization of Skin Cancer Medications
   E. Market News and Updates
   F. College of Pharmacy Recommendations
   G. Utilization Details of Skin Cancer Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

10. **Action Item – Annual Review of Crohn's Disease and Ulcerative Colitis (UC) Medications – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization of Crohn's Disease and UC Medications
    C. Prior Authorization of Crohn's Disease and UC Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of Crohn's Disease and UC Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. **Action Item – Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix I**
    A. Current Prior Authorization Criteria

B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Anticoagulants and Platelet Aggregation Inhibitors

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. Annual Review of Antidepressants and 30-Day Notice to Prior Authorize Sertraline Capsules – See Appendix J

A. Current Prior Authorization Criteria
B. Utilization of Antidepressants
C. Prior Authorization of Antidepressants
D. Market News and Updates
E. Sertraline Capsule Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Antidepressants

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Livmarli™ (Maralixibat) – See Appendix K

A. Introduction
B. Livmarli™ (Maralixibat) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Byooviz™ (Ranibizumab-nuna Injection) and Susvimo™ (Ranibizumab Intravitreal Implant) – See Appendix L

A. Introduction
B. Market News and Updates
C. Byooviz™ (Ranibizumab-nuna Injection) Product Summary
D. Susvimo™ (Ranibizumab Intravitreal Implant) Product Summary
E. College of Pharmacy Recommendations
F. Utilization Details of Ophthalmic Vascular Endothelial Growth Factor (VEGF) Inhibitor Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

15. Annual Review of Enspryng™ (Satralizumab-mwge), Soliris® (Eculizumab), Ultomiris® (Ravulizumab-cwvz), and Uplizna® (Inebilizumab-cdon) and 30-Day Notice to Prior Authorize Empaveli™ (Pegcetacoplan) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of Enspryng™ (Satralizumab-mwge), Soliris® (Eculizumab), Ultomiris® (Ravulizumab-cwvz), and Uplizna® (Inebilizumab-cdon)
C. Prior Authorization of Enspryng™ (Satralizumab-mwge), Soliris® (Eculizumab), Ultomiris® (Ravulizumab-cwvz), and Uplizna® (Inebilizumab-cdon)

D. Market News and Updates
E. Empaveli™ (Pegcetacoplan) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Enspryng™ (Satralizumab-mwge), Soliris® (Eculizumab), Ultomiris® (Ravulizumab-cwvz), and Uplizna® (Inebilizumab-cdon)

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

16. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix N

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Future Business* (Upcoming Product and Class Reviews)
No live DUR Board meeting scheduled for January 2022. January 2022 will be a packet-only meeting.

A. Antihyperlipidemics
B. Dry Eye Disease (DED) Medications
C. Glaucoma Medications
D. Gonadotropin-Releasing Hormone (GnRH) Medications

*Future product and class reviews subject to change.

18. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.